Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. gives an overview of Advaxis’ Lm Technology, which alters Listeria monocytogenes (Lm) bacteria to stimulate cancer-fighting T-cells directed against cancer antigens. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
What is Lm Technology?
